Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)	3 Months Ended		12 Months Ended
	Mar. 31, 2023	Mar. 31, 2022	Dec. 31, 2022
Cash flow from operating activities:
Net loss	$ (64,017,000)	$ (62,867,000)
Adjustments to reconcile net loss to net cash used in operations:
Depreciation and amortization	2,363,000	2,284,000
Non cash lease expense	(19,000)	(1,000)
Provision for doubtful accounts	611,000	235,000
Change in fair value of warrant liabilities	(1,735,000)	20,932,000
Goodwill impairment	29,633,000	0
Stock-based compensation expense	3,988,000	2,422,000
Change in fair value of contingent consideration	(18,932,000)	4,849,000
Acquired in-process research and development	3,000,000
Issuance of common stock for stem-cells to be used in research and development	1,000,000
Change in fair value of contingent stock consideration	(110,000)	1,565,000
Change in fair value of debt	1,280,000	0
Other, net	272,000	96,000
Changes in assets and liabilities:
Accounts receivable	791,000	(1,112,000)
Inventory	(1,813,000)	(5,670,000)
Prepaid expenses and other assets	1,463,000	(348,000)
Accounts payable	2,730,000	1,334,000
Accrued expenses and other liabilities	729,000	604,000
Accrued R&D software	23,675,000	1,333,000
Right-of-use assets and lease liabilities	64,000	52,000
Deferred revenue	32,000	39,000
Net cash used in operating activities	(14,995,000)	(34,253,000)
Cash flow from investing activities:
Capital expenditures	(209,000)	(1,454,000)
Purchase of acquired in-process research and development	(3,000,000)
Net cash used in investing activities	(3,209,000)	(1,454,000)
Cash flow from financing activities:
Proceeds from the exercise of stock options	300,000	10,000
Principal payments of short-term debt	(1,618,000)
Proceeds from issuance of senior secured bridge loan and warrants	4,994,000
Proceeds from PIPE financing	9,000,000
Proceeds from the sale of common stock in ATM offering	136,000
Proceeds from the exercise of warrants		46,485,000
Tax withholding on vesting of restricted stock units	(53,000)
Net cash provided by financing activities	12,759,000	46,495,000
Net (decrease) increase in cash, cash equivalents and restricted cash	(5,445,000)	10,788,000
Cash, cash equivalents and restricted cash at beginning of period	28,802,000	52,076,000	$ 52,076,000
Cash, cash equivalents and restricted cash at end of period	23,357,000	62,864,000	$ 28,802,000
Supplemental Cash Flow Information [Abstract]
Cash paid for interest	251,000
Supplemental non-cash investing and financing activities:
Property and equipment included in accounts payable and accrued expenses	(697,000)	(1,015,000)
Issuance of warrants on senior secured bridge loan	274,000
PIPE related costs included in accrued expenses	(69,000)
Common stock issued for short-term debt conversion	$ 3,510,000
Reclassification of option liabilities to equity		$ 441,000